Jean‐Baptiste Bachet
A5061710022- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Pancreatitis Pathology and Treatment
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Metastasis and carcinoma case studies
- Cancer, Hypoxia, and Metabolism
Sorbonne Université
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Pitié-Salpêtrière Hospital
2016-2025
Université Paris Cité
2015-2024
Centre de Recherche des Cordeliers
2019-2024
Inserm
2014-2024
Sorbonne Paris Cité
2016-2024
Université Sorbonne Nouvelle
2019-2024
Centre National de la Recherche Scientifique
2016-2023
Université Paris 1 Panthéon-Sorbonne
2019-2023
Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting oxaliplatin, irinotecan, fluorouracil, leucovorin (FOLFIRINOX) as compared with gemcitabine first-line therapy in patients metastatic pancreatic cancer.We randomly assigned 342 an Eastern Cooperative Oncology Group performance status score 0 or 1 (on scale to 5, higher scores indicating greater severity illness) receive FOLFIRINOX (oxaliplatin, 85 mg per square meter body-surface area; 180 meter;...
Among patients with metastatic pancreatic cancer, combination chemotherapy fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy safety of a modified FOLFIRINOX regimen as adjuvant therapy in resected cancer.
Abstract The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer. molecular mechanisms underlying the clinical response this drug remain unknown. Genetic alterations of intracellular effectors involved EGFR-related signaling pathways may have an effect on targeted therapy. In study, tumors from 30 cancer patients treated by were screened for KRAS, BRAF, and PIK3CA mutation direct sequencing EGFR copy number chromogenic...
Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab 30 CRC patients. The aim of this study was validate, an independent larger series 89 patients, the prognostic value on response and survival.Eighty-nine metastatic patients treated after treatment failure irinotecan-based chemotherapy analyzed for mutation by allelic discrimination tumor DNA. association between response, skin toxicity,...
Background Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant before preoperative chemoradiotherapy could reduce the risk recurrences. Methods did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France. Eligible patients were adults aged 18–75 years had newly diagnosed, biopsy-proven, adenocarcinoma...
Purpose The occurrence of KRAS mutation is predictive nonresponse and shorter survival in patients treated by anti–epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use with wild-type tumors. However, only half these will benefit from treatment, suggesting need identify additional biomarkers cetuximab-based treatment efficacy. Patients Methods We retrospectively collected tumors 173 mCRC. All but...
Oxaliplatin combined with fluoropyrimidine improves survival in patients stage III colon cancer. However, adjuvant chemotherapy oxaliplatin is controversial II and elderly patients.We performed subgroup analyses of randomly assigned fluorouracil leucovorin (FL) ± (FOLFOX4) the Multicenter International Study Oxaliplatin/Fluorouracil/Leucovorin Adjuvant Treatment Colon Cancer study. Comorbidities, severe adverse events, second cancers, management relapse death as a result causes than other...
epidemiology and risk factorsIn Europe, cancer of the pancreas is seventh most frequent cancer, accounting for some 2.8% in men 3.2% women. It fifth leading cause cancer-related death with ∼70 000 estimated deaths each year predicted to become fourth both sexes due course European Union [1.Ferlay J. Parkin D.M. Steliarova-Foucher E. Estimates incidence mortality Europe 2008.Eur J Cancer. 2010; 46: 765-781doi:10.1016/j.ejca.2009.12.014Abstract Full Text PDF PubMed Scopus (1877) Google...
Abstract Purpose: Despite recent therapeutic advances, prognosis of patients with pancreatic adenocarcinoma remains poor. Analyses from tumor tissues present limitations; identification informative marker blood might be a promising alternative. The aim this study was to assess the feasibility and prognostic value circulating DNA (ctDNA) in adenocarcinoma. Experimental Design: From 2011 2015, samples were prospectively collected all consecutive treated our center. Identification ctDNA done...
The intratumoral microenvironment, or stroma, is of major importance in the pathobiology pancreatic ductal adenocarcinoma (PDA), and specific conditions stroma may promote increased cancer aggressiveness. We hypothesized that this heterogeneous evolving compartment drastically influences tumor cell abilities, which turn PDA aggressiveness through crosstalk mediated by extracellular vesicles (EVs). Here, we have analyzed proteomic stromal signature identified a contribution annexin A6/LDL...
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...
This randomized, open-label trial compared the efficacy and safety of adjuvant
There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival consistently <4 months in this setting. The aim of study was to evaluate the efficacy tolerability Nab-paclitaxel plus gemcitabine (A+G) after Folfirinox failure MPA. From February 2013 July 2014, all consecutive patients treated with A+G histologically proven MPA were prospectively enrolled 12 French centres. delivered as described MPACT trial, until disease...
Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation Adjuvant Chemotherapy (IDEA) France, as part the IDEA international collaboration, patient with cancer were randomly assigned 3 6 months modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, oxaliplatin) or capecitabine plus oxaliplatin (CAPOX)...
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed the benefit of mFOLFIRINOX adjuvant setting. Methods: PRODIGE 24/CCTG PA.6 a phase III multicenter, randomized clinical trial. Pts aged 18-79 years histologically proven ductal adenocarcinomas, 21-84 days after R0 or R1 resection, WHO PS ≤1, adequate hematologic and renal function, no cardiac ischemia, were...
BACKGROUND Few data are available on second‐line chemotherapy (CT2) for advanced biliary tract cancer (ABTC). The aim of this multicenter study was to describe the CT2 regimens used, response rates, and outcomes patients treated with various regimens. METHODS Patients who received ABTC at 17 French institutions after failure gemcitabine‐platinum combination were retrospectively studied. Progression‐free survival (PFS) overall (OS) estimated Kaplan‐Meier method. Cox models used multivariate...